Home » Posts tagged with » Merck (Page 2)
Merck’s EMD Serono to expand biopharma R&D facility with $70m investment

German pharma company Merck will invest $70 million for the expansion of its US and Canada biopharma business EMD Serono’s research and development (R&D) facility in Billerica, Massachusetts. The expansion of the R&D facility through the addition of a new building is expected to enable drug discoveries in the areas of oncology, immuno-oncology and immunology. […]

Continue reading …
Merck bags EU approval for Keytruda chemo combo therapy for NSCLC

Merck has bagged the European Commission approval for the combination of its anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) with Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum chemotherapy for the treatment of a certain form of metastatic nonsquamous non-small cell lung cancer (NSCLC). The latest Keytruda approval is for the use of the cancer combination therapy as […]

Continue reading …
Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors

Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab) in advanced solid tumors. According to Alkermes, ALKS 4230 is an engineered fusion protein which selectively binds and signals […]

Continue reading …
Eisai, Merck bag Lenvima FDA approval for unresectable HCC

Lenvima FDA appoval : Eisai and Merck announced that the US Food and Drug Administration (FDA) has approved their kinase inhibitor Lenvima (lenvatinib) capsules for first-line treatment of hepatocellular carcinoma (HCC), a common type of primary liver cancer adults. Lenvima FDA approval, which is for HCC that is unresectable, was driven by results of the […]

Continue reading …
Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab

Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination of Voyager-V1 and Bavencio (avelumab), respectively, for metastatic colorectal cancer. According to Vyriad, Voyager-V1 is an oncolytic virotherapy which is a bullet-shaped, negative-sense RNA virus having low human seroprevalence. The […]

Continue reading …
Merck lung cancer drug Keytruda plus chemo gets FDA approval for NSCLC

Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease. The Keytruda chemotherapy combination has been approved to treat metastatic non-squamous non small cell lung […]

Continue reading …
Page 2 of 212